Larimar Therapeutics, Inc. Common Stock (LRMR) Stock
NASDAQ · LRMR
3.83
Fundamentals
Market cap
$393.72M
Price / Earnings ratio
-2.3x
Price / Sales ratio
N/A
Price / Book ratio
3.1x
Return on assets
-1.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Larimar Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees71
CEODr. Carole S. Ben-Maimon M.D.
IPO DateJun 19, 2014
HeadquartersBala Cynwyd, PA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Carole S. Ben-Maimon M.D. | CEO, President & Director | 1959 |
| Mr. Michael Celano CPA | Secretary & CFO | 1959 |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer | 1971 |
| Mr. John Berman | Vice President of Finance & Administration | — |
| Ms. Jennifer Spokes Johansson | Vice President of Legal & Compliance | — |
| Dr. Russell G. Clayton Sr., D.O. | Chief Medical Officer | 1961 |
| Mr. Francis Michael Conway CPA | VP & Controller | — |
Fundamentals
Valuation
Market cap$393.72M
Price-to-sales ratioN/A
Price-to-book value3.09
Price-earnings ratio-2.30
Return on Equity-134.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.39
Income Statement
Average volume999,838
EBITDA$-165.99M
1 year high (52w)$6.42
1 year low (52w)$2.72
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



